BACKGROUND: Depression in patients with type 2 diabetes (T2D) is often undiagnosed and remains untreated, leading to poor therapy adherence and ill health-related outcomes. We evaluated the effect of vortioxetine versus sertraline in the treatment of depression, distress and metabolic control in subjects with T2D and depression. METHODS: Participants were selected from the Clinic for Diabetes, diagnosed with depression when the score was ≥14 in the Hamilton Depression Rating Scale, and verified by a psychiatrist in agreement with the DSM-5 instrument (Diagnostic and Statistical Manual of Mental Disorders, fifth edition). The criteria for recruitment also included glycosylated hemoglobin ≥7.5%, 18 to 60 years of age, and written informed consent. Pharmacological treatment for depression was assigned randomly: vortioxetine (10 mg/day) or sertraline (75 mg/day) for 8 weeks. Biochemical parameters, anthropometric measures and depression symptoms were evaluated after antidepressant treatment. This was a randomized singled-blind study. RESULTS: Subjects that met the inclusion criteria were 50, of which only 21 patients with T2D and depression finished the treatment. Vortioxetine and sertraline showed partial remission of depression. Vortioxetine showed a major effect size in glycosylated hemoglobin and a moderate effect size on weight loss, fasting plasma glucose (FPG), cholesterol and triacylglycerol levels. On the other hand, patients treated with sertraline presented a slight increase in body weight, body mass index (BMI), and in all biochemical markers. CONCLUSIONS: Vortioxetine may ameliorate depressive symptoms and metabolic control in patients with T2D and depression. Trial registration number: NCT03978286. 2019 Annals of Translational Medicine. All rights reserved.
BACKGROUND: Depression in patients with type 2 diabetes (T2D) is often undiagnosed and remains untreated, leading to poor therapy adherence and ill health-related outcomes. We evaluated the effect of vortioxetine versus sertraline in the treatment of depression, distress and metabolic control in subjects with T2D and depression. METHODS: Participants were selected from the Clinic for Diabetes, diagnosed with depression when the score was ≥14 in the Hamilton Depression Rating Scale, and verified by a psychiatrist in agreement with the DSM-5 instrument (Diagnostic and Statistical Manual of Mental Disorders, fifth edition). The criteria for recruitment also included glycosylated hemoglobin ≥7.5%, 18 to 60 years of age, and written informed consent. Pharmacological treatment for depression was assigned randomly: vortioxetine (10 mg/day) or sertraline (75 mg/day) for 8 weeks. Biochemical parameters, anthropometric measures and depression symptoms were evaluated after antidepressant treatment. This was a randomized singled-blind study. RESULTS: Subjects that met the inclusion criteria were 50, of which only 21 patients with T2D and depression finished the treatment. Vortioxetine and sertraline showed partial remission of depression. Vortioxetine showed a major effect size in glycosylated hemoglobin and a moderate effect size on weight loss, fasting plasma glucose (FPG), cholesterol and triacylglycerol levels. On the other hand, patients treated with sertraline presented a slight increase in body weight, body mass index (BMI), and in all biochemical markers. CONCLUSIONS: Vortioxetine may ameliorate depressive symptoms and metabolic control in patients with T2D and depression. Trial registration number: NCT03978286. 2019 Annals of Translational Medicine. All rights reserved.
Entities:
Keywords:
Vortioxetine; depression; sertraline; type 2 diabetes (T2D)
Authors: A Mørk; A Pehrson; L T Brennum; S Møller Nielsen; H Zhong; A B Lassen; S Miller; L Westrich; N J Boyle; C Sánchez; C W Fischer; N Liebenberg; G Wegener; C Bundgaard; S Hogg; B Bang-Andersen; T Bryan Stensbøl Journal: J Pharmacol Exp Ther Date: 2011-12-09 Impact factor: 4.030
Authors: Fernanda Pedrotti Moreira; Karen Jansen; Taiane de Azevedo Cardoso; Thaíse Campos Mondin; Pedro Vieira da Silva Magalhães; Flávio Kapczinski; Luciano Dias de Mattos Souza; Ricardo Azevedo da Silva; Jean Pierre Oses; Carolina David Wiener Journal: J Psychiatr Res Date: 2017-04-02 Impact factor: 4.791
Authors: B E McGuire; T G Morrison; N Hermanns; S Skovlund; E Eldrup; J Gagliardino; A Kokoszka; D Matthews; M Pibernik-Okanović; J Rodríguez-Saldaña; M de Wit; F J Snoek Journal: Diabetologia Date: 2009-10-20 Impact factor: 10.122
Authors: Carlos Góis; Tiago Antunes Duarte; Sofia Paulino; João Filipe Raposo; Isabel do Carmo; António Barbosa Journal: BMC Res Notes Date: 2018-01-16